L Cho, R Dent, ESG Stroes, EA Stein,
D Sullivan… - … Drugs and Therapy, 2018 - Springer
Purpose Evolocumab reduced low-density lipoprotein cholesterol (LDL-C) in 12-week trials
in statin-intolerant patients (GAUSS-1 and GAUSS-2); however, the persistence of efficacy …